Search global stocks & ETFs...Ctrl K

Learn Mode

INCY - Incyte Corp

72

$95.31

-$2.32 (-2.376%)

At market close

$96.83

$1.52 (1.596%)

After Hours 5/15/26, 10:50 PM

Score

4.07/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

INCY

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$19.04B

Industry

Biotechnology

EPS (TTM)

$6.92

P/E (TTM)

13.30

Div & Yield

FCF Payout Ratio

P/S (TTM)

3.55

P/B

3.39

Diluted Shares

206.83M

Ex-Dividend

Next Earnings

07-27

Forward P/E

11.39

Payout Ratio

P/FCF (TTM)

13.12

FCF Yield

7.62%

Earnings Yield

7.52%

52 Week Range

Score Card

Explore Scores Tab

4.07

Good

Incyte Corp has grown revenue at 21.48% over the past year, which is strong growth. Also, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

5.00

Very Good

Management

3.00

Average

Growth

4.00

Good

Profitability

2.00

Bad

Fin. Health

2.00

Bad

Dividends

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

3 new filings were in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-05-14 12:47:22

Form SCHEDULE 13D/A

Unknown Form Type

Filed on 2026-05-11 16:59:57

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-11 16:45:25

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-06 16:34:55

Form 3

Initial statement of beneficial ownership of securities - general instructions

Filed on 2026-05-06 16:34:13

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-04-30 10:30:26

Form ARS

Unknown Form Type

Filed on 2026-04-28 16:27:01

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-28 16:26:36

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-28 16:25:54

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-04-28 16:02:46

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-28 07:03:17

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-21 16:09:07

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$141.75

48.7%

Avg:

$109.42

14.8%

Low:

$72.83

-23.6%

(% change is relative to the current stock price: $95.31)

Analyst Recommendations

Go to Analyst Tab

3.70

Good

24%

Strong Buy (8)

24%

Buy (8)

48%

Hold (16)

Sell (1)

Strong Sell (0)

About

Website
https://www.incyte.com/
Address
1801 Augustine Cut-Off, Wilmington DELAWARE, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=879169

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

IPO Date

1993-12-06

Industry

Biotechnology

Total Employees

2,844

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

INCY - Incyte Corp

72

$95.31

-$2.32 (-2.376%)

$96.83

$1.52 (1.596%)

4.07/5

Stock Unlock

Stock Profile

Score Card

Good

Insider Transactions

Market News

Form SCHEDULE 13G/A

Filed on 2026-05-14 12:47:22

Form SCHEDULE 13D/A

Filed on 2026-05-11 16:59:57

Form 4

Filed on 2026-05-11 16:45:25

Form 4

Filed on 2026-05-06 16:34:55

Form 3

Filed on 2026-05-06 16:34:13

Form SCHEDULE 13G

Filed on 2026-04-30 10:30:26

Form ARS

Filed on 2026-04-28 16:27:01

Form DEFA14A

Filed on 2026-04-28 16:26:36

Form DEF 14A

Filed on 2026-04-28 16:25:54

Form 10-Q

Filed on 2026-04-28 16:02:46

Form 8-K

Filed on 2026-04-28 07:03:17

Form 4

Filed on 2026-04-21 16:09:07

Financials

Price Targets

48.7%

14.8%

-23.6%

Analyst Recommendations

About

Similar Stocks